BG
COAG

Bellevue Group’s Hemab Therapeutics COAG Stock Holding History

Bellevue Group’s Portfolio COAG Stock Details COAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2M Buy
+550,000
New +$15.2M 0.43% 53

Other funds holding COAG

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Bellevue Group's COAG Position: Q2 2026 in Review

Bellevue Group opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 550,000 shares worth $20.2M. The stake represents 0.43% of the portfolio and ranks #53 among its holdings.

44 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

  • Bellevue Group held 550,000 shares of Hemab Therapeutics worth $20.2M as of Q2 2026.
  • Hemab Therapeutics was a new Bellevue Group position in Q2 2026.
  • Hemab Therapeutics made up 0.43% of Bellevue Group's portfolio in Q2 2026, its #53 holding.
  • 44 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.